Description
Retatrutide 10mg — triple receptor agonist for metabolic research in Australia. University-verified ≥99% purity. Same-day Sydney dispatch.
Retatrutide (LY3437943) activates three receptors simultaneously: GLP-1, GIP, and glucagon. This triple mechanism distinguishes it from dual agonists like tirzepatide, making it one of the most studied compounds in current metabolic research.
What the Research Shows
Phase 2 clinical trials published in the New England Journal of Medicine documented significant effects on body composition. The compound’s glucagon receptor activity adds a thermogenic component absent from GLP-1-only analogues.
Researchers investigate how the triple receptor profile affects appetite signalling, glucose homeostasis, and hepatic lipid metabolism. Published data provides well-characterised pharmacokinetics for study design.
Why Australian Researchers Choose Purpose Labs
Every batch is tested at a leading Australian university — HPLC and mass spectrometry confirm ≥99% purity. No generic overseas certificates.
→ Full Retatrutide Research Guide
Purity: ≥99% (HPLC)
Form: Lyophilised powder
Molecular Weight: 4,471.52 Da
Sequence: 39 amino acids
Targets: GLP-1R / GIPR / GCGR
Research: PubMed
▸ Australian university verified
▸ ≥99% purity guaranteed
▸ Same-day dispatch from Sydney
▸ Research-grade lyophilised powder
Related Research and Resources
For research use only. Not for human consumption.
